First Director Named for NHGRIs New Division of Genomics and Society
Lawrence C. Brody, PhD, a pioneering genetics and genomics researcher, has been selected to be the first director of the newly established Division of Genomics and Society at the National Human Genome Research Institute (NHGRI). Dr Brody is currently chief of the Genome Technology Branch within NHGRI’s intramural research programme, and the chief scientific officer of the trans-NIH Center for Inherited Disease Research. NHGRI is one of the 27 institutes and centers that make up the National Institutes of Health.
Dr Brody’s expertise and interests are wide-ranging, from human genetics and genomics to the public understanding of science. As a bench scientist, he played an instrumental role in early and important discoveries about the BRCA1 gene, which is responsible for a hereditary form of breast cancer. His research efforts have regularly included studying the practical implications of genomic advances. For example, Dr Brody was a co-architect of the NHGRI Multiplex Initiative, an innovative project that aimed to better understand how the general public comprehends and reacts to personal genetic testing results.
Dr Brody has also invested a considerable amount of his professional efforts to addressing the broader societal issues relevant to contemporary genomics research. He has worked on several projects related to genomics, society, and minority populations and, most recently, he served as a key developer of the public exhibition, Genome: Unlocking Life’s Code, which opened in June at the Smithsonian Institution’s National Museum of Natural History. Moreover, on multiple occasions, he worked closely with the US Solicitor General in the drafting and editing of legal briefs and in the preparation of oral arguments for the gene patenting case that went before the US Supreme Court earlier this year.
“Dr Brody brings an extraordinary and diverse body of accomplishments and expertise to lead this newly created division,” said NHGRI Director Eric D. Green, MD, PhD. “His perspective as a bench scientist combined with a demonstrated long-term interest in the intersection of science and society makes him uniquely qualified to lead this critical part of NHGRI’s research programme.”
The Division of Genomics and Society was established in 2012 as part of an institute-wide reorganisation. It is one of four divisions that make up the institute’s extramural research programme. This new division is now responsible for an expanded programme related to the many societal issues relevant to genomics research and genomic advances, incorporating and extending the activities of NHGRI’s Ethical, Legal and Social Implications (ELSI) research programme. The latter was established in 1990 as part of the Human Genome Project and aims to pursue multidisciplinary research and training designed to explore the impact of genomics on society.
“It is an exciting time for genetics and genomics, but with that comes the responsibility to examine and address the many important societal implications of these research advances. With improvements in technology as the driving force, genomics can increasingly be used in clinical settings in a way that was simply not possible a decade ago,” Dr Brody said. “Because genomics is moving closer to our daily lives, we need to better understand its societal impact. Issues such as consent, privacy, and access to genomic information will continue to grow in importance. We need to increasingly pursue research to understand these issues and to engage relevant stakeholders, including the general public, in the discussions.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance